Bristol Myers Squibb

Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company headquartered in Princeton, NJ, with ~34,000 employees, focused on oncology, hematology, immunology and cardiovascular medicines. Its most AGD-relevant footprint is its cell therapy (autologous CAR-T) manufacturing network — Bothell WA, Warren and Summit NJ, Devens MA, and Leiden NL — producing Abecma and Breyanzi. The Devens, MA campus (89 acres, ~1,700 employees) houses a 244,000 sq ft cell therapy facility (FDA-approved for commercial production in 2023) and is heavily invested in automation/AI; it was named a World Economic Forum Global Lighthouse in 2026. BMS is actively building automated/robotic cell therapy manufacturing capability (it staffs Robotics Process Engineers at the Devens CTF). BMS has been divesting traditional sterile fill-finish drug-product sites — Anagni, Italy to Catalent (2020) and its Phoenix, AZ sterile injectable facility to ROIS/ROVI (closed early 2026) — concentrating its in-house manufacturing on biologics and personalized cell therapies, where contact-rich manual handling (sterile tubing connections, flexible bag manipulation) remains a recognized bottleneck.